jama glp 1 Study comparing Mounjaro and Ozempic published in JAMA Internal Medicine

First Time: Orally Available GLP-1 Agonist More Effective than DPP-IV Inhibitor | DZD

21.32

★★★★☆4.8 (126)

Today, the World Health Organization (WHO) published a guideline in JAMA for the management of adult #obesity, recommending long-term #GLP1 therapy for weight control. Conditional recommendations include pairing medication with intensive behavioral

24.88

★★★★★4.9 (98)

New JAMA Data Brief 📊 About 1 in 5 US adults with type 2 diabetes were already using the popular class of medications called glucagon-like peptide 1 (GLP-1) receptor agonists by 2022,

28.35

★★★★★5.0 (157)

In a major new JAMA Oncology study, researchers examined health records from 86,632 adults with obesity, comparing those who used GLP-1 receptor agonists (like semaglutide or tirzepatide) to matched non-users. The findings

29.05

★★★★★4.7 (84)

Study comparing Mounjaro and Ozempic published in JAMA Internal Medicine

26.38

★★★★★4.9 (203)

Many adults stop GLP-1 therapy within a year with low restart rates, analysis finds

28.03

★★★★★5.0 (176)

So what does this study tell us about GLP-1 agonists before pregnancy. It tells us that weight regain when stopping them is a real concern and that we need to support people transitioning off to

23.45

★★★★★4.8 (132)